Oncternal (ONCT) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Graphic logo of Oncternal (ONCT)

Oncternal Therapeutics operates in the solid and hematological tumor therapy segment, where a shortage of effective solutions persists. The company is developing a unique antibody, ciltuzig, to combat resistant forms of breast and blood cancer by suppressing the ROR1 protein. This EV/EBITDA chart captured the metric at . The team consists of leading oncologists attracted by cutting-edge research and competitive employment terms.

ONCT Oncternal Therapeutics Inc: Enterprise Value to Operating Income Before Depreciation in the range 07/04/2022 - 11/12/2026

ONCT (oncternal.com): analytical breakdowns and indicator data

- stock price and consensus target price:
Stock Quotes Oncternal|ONCT - Fair Value Consensus
- market capitalization indicators:
Market Value Oncternal Corp|ONCT - Total Enterprise Value
- book value of equity indicators:
Net Assets per Single Share Oncternal Therapeutics|ONCT - Accounting Capitalization|Market Capitalization to Book Value Ratio oncternal.com|ONCT - Cumulative Company Assets
- debt and liquidity data:
Debt to Equity Oncternal Therapeutics|ONCT - Long-Term Liabilities to Capital|Short-Term Debt to Equity Oncternal Therapeutics, Inc.|ONCT - Company Debts|Debt to Book Capitalization Ratio Oncternal Corp|ONCT - Long-Term Debt|Company Short-Term Debts Oncternal Therapeutics|Quick Liquidity Indicator oncternal.com
- business earnings and investment ratios data:
ONCT - Company Net Income|Future Profit Oncternal Therapeutics|ONCT - Company Value to Net Income|Projected Price to Earnings Oncternal Therapeutics|ONCT - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Oncternal Corp|ONCT - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Oncternal Therapeutics|ONCT - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months oncternal.com|ONCT - Earnings per share increase in current year|Earnings growth forecast for next year Oncternal Therapeutics
Summary company analytics:ONCT (Oncternal)
Original product of Oncternal Therapeutics, Inc.

The multiple correlates the total enterprise value, including net debt, with operating profit before taxes, depreciation, and amortization. This indicator determines the cost of one dollar of EBITDA, allowing an investor to identify whether an asset is overvalued or undervalued relative to market expectations. For Oncternal Therapeutics (ONCT), which minimizes operational risks through an extensive network of external laboratories, the historical EV/EBITDA trajectory reflects the efficiency of this capital-intensive model.

Competitor analysis

Incyte Corp. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation HCM|NUVB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA dayonebio.com|Monopar Therapeutics Inc. (MNPR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation INBX|IMAB (I-Mab Biopharma Co., Ltd.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Fennec (FENC)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Heron Therapeutics (HRTX)|NVCT - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Coherus BioSciences Inc. CHRS|Corbus Pharmaceuticals Holdings, Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CRDF - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA BeyondSpring Inc|BCAB: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple lixte.com LIXT|Enterprise Value to EBITDA Ratio CTXR|Company Value to EBITDA Cellectar Biosciences Inc CLRB|Enterprise Value to EBITDA Ratio BLRX (BioLineRx Corp)|CANF (Can-Fite) - Business Value to Operating Income Before Depreciation|Aprea Therapeutics, Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio KZIA (Kazia Therapeutics Ltd)|Silexion - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation NCNA (NuCana plc)|CMRX: EV/EBITDA Multiple|Company Value to EBITDA Cyclacel, Inc. (CYCC)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization G1 Therapeutics Inc.|KRON: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple KTRA|EV/EBITDA Multiple Portage Biotech Inc (PRTG)